Literature DB >> 31210793

A unique presentation of destructive shoulder arthropathy in the chronic phase of chronic myeloid leukaemia.

Joshua Howard1, Benedict Mackenzie1, Toby Nicholson1, Sylvia Connolly1, Rishee Parmar1.   

Abstract

We present a previously unreported case of rapidly progressing, destructive shoulder arthropathy as an initial presentation of chronic phase chronic myeloid leukaemia. This patient initially presented to clinic for consideration of an arthroplasty for symptom relief; however, her loss to follow-up yielded a rapid progression of her symptoms. Bone marrow aspirate and targeted biopsy of the humeral head excluded blast cell crisis, in contrast to previously reported cases. She was treated conservatively with medical management of her underlying disease. Although leukaemic arthritis is a recognized phenomenon, chronic myeloid leukaemia is not known to cause bone destruction of this kind, particularly in the absence of blast crisis. Medical treatment with a tyrosine kinase inhibitor provided a dramatic improvement in our patient's pain, without the risk of attempted arthroplasty in unknown bone quality. We describe a unique presentation of severe bone destruction as a manifestation of chronic myeloid leukaemia in the absence of blast crisis. This should be considered as a rare differential diagnosis in joint arthropathy and may be appropriately managed initially with medical therapy, whereas future arthroplasty comprises uncharted territory in unknown bone quality.

Entities:  

Keywords:  blast cell crisis; chronic myeloid leukaemia; chronic phase; leukaemic arthritis; shoulder arthropathy; tyrosine kinase inhibitor

Year:  2017        PMID: 31210793      PMCID: PMC6555107          DOI: 10.1177/1758573217715260

Source DB:  PubMed          Journal:  Shoulder Elbow        ISSN: 1758-5732


  14 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  The skeletal lesions of acute leukemia.

Authors:  L B THOMAS; C E FORKNER; E FREI; B E BESSE; J R STABENAU
Journal:  Cancer       Date:  1961 May-Jun       Impact factor: 6.860

Review 3.  Treatment of chronic myeloid leukemia in blast crisis.

Authors:  R Hehlmann; S Saussele
Journal:  Haematologica       Date:  2008-12       Impact factor: 9.941

4.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Authors:  Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

5.  Leukemic synovitis as a presentation of myelomonocytic blast crisis of chronic myeloid leukemia.

Authors:  H M Al-Rayes; A A Al-Shaikh; M A Halim; F S Al-Qurashi; M M Al-Jurf
Journal:  Saudi Med J       Date:  2001-09       Impact factor: 1.484

6.  Acute lymphoblastic leukaemia presenting with arthritis in an adult patient.

Authors:  C Usalan; E Ozarslan; N Zengin; Y Büyükaýk; Y H Güllü
Journal:  Postgrad Med J       Date:  1999-07       Impact factor: 2.401

Review 7.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

Review 8.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

Review 9.  Chronic myelogenous leukemia, BCR-ABL1+.

Authors:  James W Vardiman
Journal:  Am J Clin Pathol       Date:  2009-08       Impact factor: 2.493

10.  Synovial fluid immunocytology in the diagnosis of leukemic synovitis.

Authors:  A G Fam; C Voorneveld; J B Robinson; B L Sheridan
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.